Journal article
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
Abstract
BACKGROUND: Prophylaxis for venous thromboembolism is recommended for at least 10 days after total knee arthroplasty; oral regimens could enable shorter hospital stays. We aimed to test the efficacy and safety of oral rivaroxaban for the prevention of venous thromboembolism after total knee arthroplasty.
METHODS: In a randomised, double-blind, phase III study, 3148 patients undergoing knee arthroplasty received either oral rivaroxaban 10 mg …
Authors
Turpie AG; Lassen MR; Davidson BL; Bauer KA; Gent M; Kwong LM; Cushner FD; Lotke PA; Berkowitz SD; Bandel TJ
Journal
The Lancet, Vol. 373, No. 9676, pp. 1673–1680
Publisher
Elsevier
Publication Date
5 2009
DOI
10.1016/s0140-6736(09)60734-0
ISSN
0140-6736
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, OralAgedAnalysis of VarianceAnticoagulantsArthroplasty, Replacement, KneeDouble-Blind MethodEnoxaparinFemaleFollow-Up StudiesHemorrhageHumansIncidenceMaleMiddle AgedMorpholinesPhlebographyRisk Reduction BehaviorRivaroxabanSensitivity and SpecificityThiophenesTreatment OutcomeVenous Thrombosis